CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 149 enrolled
Drug / intervention
ETX-018810 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04778592
NCT04778592Phase 2Completed

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ETX-018810 in Subjects With Lumbosacral Radicular Pain

Eliem Therapeutics (UK) Ltd.·interventional·Posted Mar 3, 2021·Updated Nov 7, 2023

In Brief

A Phase 2 clinical trial evaluating ETX-018810 and Placebo for Lumbosacral Radiculopathy. Completed, enrolled 149 participants across 24 sites.

Detailed Summary

Efficacy and Safety of ETX 018810 in Subjects with Lumbosacral Radicular Pain

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedMar 3, 2021
Enrollment StartJan 19, 2021
Primary CompletionMay 16, 2022
Study CompletionMay 25, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 5.3 years ago

Interventions

ETX-018810drug

Study Drug

Placebodrug

Placebo